Benevolent AI (Benevolent AI) Gross-Profit-to-Asset % : 5.98% (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Benevolent AI Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Benevolent AI's annualized Gross Profit for the quarter that ended in Dec. 2023 was $10.30 Mil. Benevolent AI's average Total Assets over the quarter that ended in Dec. 2023 was $172.13 Mil. Therefore, Benevolent AI's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 5.98%.

Benevolent AI Gross-Profit-to-Asset % Historical Data

The historical data trend for Benevolent AI's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benevolent AI Gross-Profit-to-Asset % Chart

Benevolent AI Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

3.89

4.67

3.82

7.36

4.84

Benevolent AI Quarterly Data
	Dec18	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial				12.78	11.83	11.00	12.92	5.98

Competitive Comparison of Benevolent AI's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Benevolent AI's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Benevolent AI's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benevolent AI's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Benevolent AI's Gross-Profit-to-Asset % falls into.

Benevolent AI Gross-Profit-to-Asset % Calculation

Benevolent AI's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	9.28	/	( (226.495	+	156.748)	/ 2 )
	=	9.28	/	191.6215
	=	4.84 %

Benevolent AI's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	10.3	/	( (187.513	+	156.748)	/ 2 )
	=	10.3	/	172.1305
	=	5.98 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Benevolent AI Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Benevolent AI's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Benevolent AI (Benevolent AI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benevolent AI (GREY:BAIVF) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

BAI:Netherlands 2XA:Germany

Address

4-8 Maple Street, London, GBR, W1T 5HD

Website

https://www.benevolent.com

Benevolent AI is a clinical-stage AI-enabled drug discovery company. It delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies.